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INTRODUCTION Background
Intubation is a critical procedure commonly performed in the emergency department (ED) setting. ED intubations typically entail rapid sequence intubation, with coadministration of a sedative agent and a paralytic medication. 1 The 2 most commonly used rapid-acting paralytics in the ED setting are succinylcholine and rocuronium. 2 ED providers have historically used succinylcholine for the majority of ED intubations.
Editor's Capsule Summary
What is already known on this topic Although commonly used in emergency department rapid sequence intubation, succinylcholine and rocuronium have different speed of onset and adverse effects.
What question this study addressed Do first-pass intubation success and adverse event rates differ between succinylcholine and rocuronium?
What this study adds to our knowledge In this analysis of 4,275 intubations from the National Emergency Airway Registry, succinylcholine and rocuronium exhibited no differences in first-pass success (87.0% versus 87.5%) or adverse events (14.7% versus 14.8%).
How this is relevant to clinical practice
Perceived intubating differences between succinylcholine and rocuronium may not be clinically important. A clinical trial is needed to confirm these observations. many of which may not always be readily apparent during emergency intubation. 6 Although the anesthesia literature suggests better conditions for rapid sequence intubation with succinylcholine than rocuronium, 7 the best paralytic for ED rapid sequence intubation remains unknown.
Goals of This Investigation
The goal of this study was to compare first-pass intubation success and peri-intubation adverse events between rapid sequence intubation performed with succinylcholine versus rocuronium.
MATERIALS AND METHODS Study Design and Setting
We analyzed data from the National Emergency Airway Registry (NEAR), a prospective registry of ED intubations performed at an international network of academic hospitals. Each of these participating sites obtained approval from its local institutional review board to conduct the study.
Methods of Measurement and Data Collection and Processing
There have been multiple previous iterations of NEAR, spanning 1996 to 2012. 1, 8 With each phase, the data collection methodology has evolved. Intubating providers at each participating site for the present iteration used a standard data collection instrument to provide information about each patient encounter involving intubation or another advanced airway management technique. 9 Variables included patient demographics, body habitus and estimated weight, impression of airway difficulty, reduced neck mobility (eg, presence of cervical collar), airway characteristics (eg, mouth opening, Mallampati score), intubation position and device, medications and doses, operator characteristics, first-pass intubation success or failure, adverse events, and patient disposition. Sites uploaded data into a centralized Web-based data management database (StudyTRAX; version 3.47.0011; ScienceTRAX, Macon, GA). After data upload, study investigators reviewed all data, using quality assurance algorithms to identify and correct data entry errors. Each participating center had a designated site investigator ensuring entry of greater than or equal to 90% of all intubations performed in his or her ED. Each site investigator prepared and submitted a study compliance plan approved by the coordinating center (Brigham and Women's Hospital, Boston, MA). These plans specified methods for using electronic billing or procedure reports to identify numbers of intubations performed at each center monthly. The coordinating center then cross-referenced numbers of intubations performed at each site against numbers of intubations entered into the NEAR database to determine the overall proportion of intubations captured. Each participating site obtained approval from its institutional review board to participate in the registry. We reported all data in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology statement. 10 
Selection of Participants
We included patients older than 14 years whose data had been entered into the NEAR database from January 1 through December 31, 2016. Periods of participation vary for individual centers because facilities joined NEAR on a rolling basis. Inclusion criteria included receipt of succinylcholine or rocuronium before the first intubation attempt. We excluded patients with missing data or data inconsistencies precluding determination of age. We did not exclude patients with other missing data unrelated to these variables.
Outcome Measures
The primary outcome was first-pass intubation success. For the purposes of the NEAR data collection forms, we defined an intubation attempt as any single effort to place an endotracheal tube in which the leading edge of the laryngoscope blade entered the oral cavity past the alveolar ridge. Secondary outcomes included incidence of any adverse event. We defined an adverse event as the occurrence of any of the following events captured by the NEAR data collection forms, all of which were diagnosed clinically by the intubating provider except where otherwise specified: cardiac arrest (loss of pulses during or immediately after intubation), dental trauma, direct airway injury, dysrhythmias, epistaxis, esophageal intubation (per clinical diagnosis, visualization, or capnography), hypotension (systolic blood pressure <100 mm Hg), hypoxia (oxygen saturation <90%), iatrogenic bleeding, laryngoscope failure, laryngospasm, lip laceration, main-stem bronchus intubation (as diagnosed clinically or by chest radiograph), malignant hyperthermia, medication error, pharyngeal laceration, pneumothorax (diagnosed clinically or by chest radiograph), endotracheal tube cuff failure, or vomiting (forceful expulsion of gastric contents). Other outcomes examined included best Cormack-Lehane view 11 and lowest peri-intubation oxygenation saturation.
Primary Data Analysis
We first compared the primary outcome of first-pass intubation success between encounters with succinylcholine versus rocuronium by calculating risk difference with 2-sided 95% confidence interval (CI). We also compared first-pass intubation success stratified by paralytic agent across participating sites, using a Cochran-Mantel-Haenszel c 2 test. We then constructed a logistic regression model to compare the odds of first-pass intubation success between these 2 paralytic agents. Nominal covariates included sex (male versus female), body habitus (very thin/thin versus normal versus obese/morbidly obese), indication (medical versus traumatic), initial impression of difficult airway (yes versus no), intubation position (full sniffing versus neutral versus other), laryngoscope type (video versus direct), induction medications (etomidate versus ketamine versus other), operator characteristics (nonemergency medicine versus emergency medicine postgraduate year 1/postgraduate year 2 versus emergency medicine postgraduate year 3/4 versus emergency medicine fellow/attending physician), and paralytic used (succinylcholine versus rocuronium). In the interest of reducing the number of collinear predictors in the model, we created the composite variable of "difficult airway characteristics" and assigned a "yes" if the patient had at least one of the following: reduced neck mobility (eg, presence of a cervical collar), Mallampati score greater than 1, reduced mouth opening, airway obstruction, facial trauma, or blood or vomit in the airway. We included "difficult airway characteristics" in the model as a nominal variable (yes versus no), and we included age and weight as continuous covariates. We accounted for clustering by site in the data set by using the Taylor series linearization method with the Morel adjustment to estimate the covariance matrix of the regression coefficients in the logistic regression models. 12 We followed a similar strategy for analyzing adverse events.
We conducted subgroup analyses by calculating the odds ratio of first-pass intubation success between paralytic types (succinylcholine versus rocuronium) for each level of the following variables: age (<65 years, 65 years), sex (male, female), body habitus (very thin/thin, normal, obese/ morbidly obese), weight (<100 kg, 100 kg), body mass index (<30 kg/m 2 , 30 kg/m 2 ), indication (medical, traumatic), presence of head injury or intracranial hemorrhage (yes, no), initial impression of difficult airway (yes, no), difficult airway characteristics (yes, no), oxygen saturation at start of intubation attempt (<90%, 90%), laryngoscope type (direct, video), and induction medications (etomidate, ketamine, other). We repeated this process twice, using only high doses of each paralytic (succinylcholine at 1.5 mg/kg versus rocuronium at 1.2 mg/kg) and rocuronium stratified by dose (rocuronium at 1.2 versus <1.2 mg/kg).
We excluded from the logistic regression models cases with missing data for any variables included as model covariates by listwise deletion. To prevent exclusion of significant proportions of cases, we did not include variables with greater than or equal to 5% data missing. We conducted all statistical analyses with SAS (version 9.4; SAS Institute, Inc., Cary, NC).
RESULTS
During the study period, 5,244 intubation encounters occurred at 22 participating centers. NEAR collected data on 5,071 encounters (96.7% data capture). We included 2,275 intubation encounters using succinylcholine and 1,800 encounters using rocuronium (Figure 1 ). The mean dose of succinylcholine administered was 1.8 mg/kg (median 1.6 mg/kg), whereas the mean dose of rocuronium administered was 1.2 mg/kg (median 1.1 mg/kg). Table 1 displays baseline characteristics, stratified by paralytic category. Patients receiving succinylcholine were younger and less obese. Proportions of patients with difficult airway characteristics were comparable between the 2 groups. Patients receiving succinylcholine were also more likely to undergo intubation with video laryngoscopy and more likely to undergo intubation by more experienced providers.
First-pass intubation success was 87.0% among succinylcholine encounters and 87.5% among rocuronium encounters (risk difference 0.5%; 95% CI -1.6% to 2.6%) ( Table 2 ). First-pass intubation success was similar when stratified by NEAR site (Cochran-Mantel-Haenszel c 2 0.1; P¼.79) (Figure 2 ). Achievement of Cormack-Lehane grade 1 to 2 view on first intubation attempt was 88.5% for succinylcholine and 89.0% for rocuronium (Table 2) . On multivariate analysis, first-pass intubation success was similar between succinylcholine and rocuronium after adjustment for difficult airway characteristics, indication for intubation, patient demographics, airway characteristics, intubation position, device, sedative agent, and intubator experience (odds ratio 0.9; 95% CI 0.6 to 1.3) ( Table 3) .
Subgroup analyses revealed similar first-pass intubation success between rocuronium and succinylcholine when stratified by patient characteristics, intubation modality, and sedative agent (Table E1 , available online at http:// www.annemergmed.com). The only significant difference noted in comparisons was higher first-pass intubation success among patients without any difficult airway characteristics who were treated with high-dose rocuronium (1.2 mg/kg) versus low-dose rocuronium (<1.2 mg/kg) (odds ratio 2.2; 95% CI 1.2 to 3.4).
Adverse events occurred in 14.7% of succinylcholine encounters versus 14.8% of rocuronium encounters (Table 4) . Two or more adverse events occurred for 2.2% of succinylcholine encounters and 2.2% of rocuronium encounters in the data set. The most common adverse events included peri-intubation hypoxia and hypotension. There was no association between the incidence of any peri-intubation adverse event and paralytic agent (odds ratio 1.1; 95% CI 0.9 to 1.3).
LIMITATIONS
Confounding is a risk in any observational study of this nature. Our analysis suggests a lack of association between paralytic choice and rapid sequence intubation outcomes but does not establish the presence or absence of a causal relationship between these variables, given this risk of confounding. Compared with the rocuronium encounters, the succinylcholine encounters included patients who were younger, less obese, and more likely to undergo intubation with video laryngoscopy, and undergo intubation by more experienced providers. Factors such as provider preference or patient contraindications (eg, hyperkalemia, neurologic conditions) may have biased the analysis. However, our observations were consistent across different subgroups.
NEAR also lacks data on other variables of clinical relevance. In particular, our data do not include times from paralytic administration to paralysis onset or offset, both of which are shorter for succinylcholine. 13 The literature discusses the possibility that these pharmacokinetics confer a clinical benefit to patients receiving succinylcholine by shortening the dangerous period during which they may not take spontaneous respirations. 2 Although small differences in paralysis onset may be unimportant for some patients, the time advantage may be important for select acutely ill patients. Examples might include patients with severe hypoxemia or profound acidosis, patient populations on which future investigations might focus.
A final limitation is that our self-reported data are susceptible to recall bias, with the potential for errors such as underreporting adverse events or overreporting intubation success. We surmise that such biases would be evenly distributed between paralytic groups. We strived to minimize such errors by requiring entry of 90% or more of all intubation encounters and encouraging completion of data forms by intubating providers as soon as possible after an intubation procedure.
DISCUSSION
The most commonly used paralytics in ED rapid sequence intubation are succinylcholine and rocuronium. 2 The existing literature suggests that succinylcholine has several advantages, including faster onset, faster offset, and superior intubating conditions. 7 Our multicenter observational study found no association between choice of paralytic and first-pass intubation success.
The most recent Cochrane review and meta-analysis concluded that succinylcholine resulted in superior intubating conditions compared with rocuronium. 7 There are several potential reasons why our study results BMI, Body mass index; IQR, interquartile range; PGY, postgraduate year. *Difficult airway characteristics coded as yes if the patient had at least one of the following: reduced neck mobility, Mallampati score greater than 1, reduced mouth opening, airway obstruction, facial trauma, and blood or vomit in airway.
differed from those of the Cochrane review. First, most of the studies included in the Cochrane review were randomized controlled trials conducted in operating room settings. Conversely, NEAR gathers observational data only on intubations performed in the ED setting, which poses distinct challenges such as noise, more critically ill patients, and limited time to optimize preintubation patient hemodynamics and equipment setup. Second, the primary outcome measured by most of studies included in the Cochrane review was intubation condition as measured by the Goldberg scale, which incorporates operator assessment of ease of intubation, vocal cord movement, and patient response to intubation. 14, 15 We instead measured outcomes we believe to be more patient centered and thus more clinically relevant, including first-pass intubation success and incidence of peri-intubation adverse events. Third, the Cochrane review included subgroup analyses finding better intubating conditions, with analysis restricted to studies examining succinylcholine compared with rocuronium dosed at 0.6 mg/kg, [16] [17] [18] but comparable intubating conditions with high-dose (1.2 mg/kg) rocuronium. 7 The mean dose of rocuronium administered in the encounters we report was relatively high, at 1.2 mg/kg, which may have contributed to our finding of no association between paralytic agent and first-pass intubation success.
Our finding of no association between paralytic and first-pass intubation success, glottic view, or incidence of adverse events is important, given the potential contraindications to succinylcholine use. Administration of succinylcholine in the setting of disorders upregulating muscle nicotinic acetylcholine receptors can result in acute hyperkalemia because of the flow of intracellular potassium into the plasma. Many clinicians may not be privy to the presence of these pathologic states at the intubation. 6 In contrast, the only established absolute contraindication to rocuronium use is hypersensitivity reaction. 19 To the extent that these medications otherwise result in similar intubation outcomes, it stands to reason that rocuronium is preferable as the default first-line paralytic agent.
NEAR does not include many data parameters pertinent to paralytic choice. Specifically, it does not include measures of muscle relaxation and intubation conditions except indirectly through reported best Cormack-Lehane glottic view. 11 We did capture encounters with peri-intubation *Any adverse event includes airway trauma, hypoxia, vomiting, dysrhythmias, cardiac arrest, hypotension, esophageal intubation, failed airway with cricothyrotomy, dental trauma, epistaxis, lip laceration, laryngospasm, main-stem intubation, pneumothorax, endotracheal tube cuff failure, iatrogenic bleeding, and laryngoscope failure. † Difficult airway characteristics coded as yes if patient had at least one of the following: reduced neck mobility, Mallampati score greater than 1, reduced mouth opening, airway obstruction, facial trauma, and blood or vomit in the airway. Given these limitations, we cannot make any inferences about causal relationships. Although our results appear to contradict previous data suggesting superior intubating conditions with succinylcholine, without an interventional trial we cannot conclude that succinylcholine is not superior to rocuronium in regard to first-pass intubation success. As such, we believe it would be premature for emergency physicians to guide their paralytic choice according to this report. Nevertheless, our data highlight that a clinical trial comparing these agents in the ED setting would be a valuable contribution to the literature.
In conclusion, we observed no difference between paralytic type and first-pass intubation success. Similarly, we found no association between paralytic type and the incidence of peri-intubation adverse events. Further study is necessary to clarify any causal relationships between paralytic agent choice and ED intubation outcomes.
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